4.4 Article

Precision Control of CRISPR-Cas9 Using Small Molecules and Light

期刊

BIOCHEMISTRY
卷 58, 期 4, 页码 234-244

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.biochem.8b01202

关键词

-

资金

  1. Burroughs Wellcome Fund (Career Award at the Scientific Interface)
  2. DARPA [Brdi N66001-17-2-4055]
  3. National Institutes of Health [1R21AI126239-01]
  4. Army Research Office [W911NF1610586]
  5. U.S. Department of Defense (DOD) [W911NF1610586] Funding Source: U.S. Department of Defense (DOD)

向作者/读者索取更多资源

The CRISPR (clustered regularly interspaced short palindromic repeat)-Cas system is an adaptive immune system of bacteria that has furnished several RNA-guided DNA endonucleases (e.g., Cas9) that are revolutionizing the field of genome engineering. Cas9 is being used to effect genomic alterations as well as in gene drives, where a particular trait may be propagated through a targeted species population over several generations. The ease of targeting catalytically impaired Cas9 to any genomic loci has led to development of technologies for base editing, chromatin imaging and modeling, epigenetic editing, and gene regulation. Unsurprisingly, Cas9 is being developed for numerous applications in biotechnology and biomedical research and as a gene therapy agent for multiple pathologies. There is a need for precise control of Cas9 activity over several dimensions, including those of dose, time, and space in these applications. Such precision controls, which are required of therapeutic agents, are particularly important for Cas9 as off-target effects, chromosomal translocations, immunogenic response, genotoxicity, and embryonic mosaicism are observed at elevated levels and with prolonged activity of Cas9. Here, we provide a perspective on advances in the precision control of Cas9 over aforementioned dimensions using external stimuli (e.g., small molecules or light) for controlled activation, inhibition, or degradation of Cas9.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据